Phase I/II Study of Azacitidine (AZA) with Venetoclax (VEN) and Magrolimab (Magro) in Patients (pts) with Newly Diagnosed Older/Unfit or High-Risk Acute Myeloid Leukemia (AML) and Relapsed/Refractory (R/R) AML
暂无分享,去创建一个
M. Konopleva | H. Kantarjian | G. Garcia-Manero | T. Kadia | F. Ravandi | G. Borthakur | E. Jabbour | N. Daver | C. Dinardo | J. Ning | N. Pemmaraju | S. Loghavi | G. Tang | H. Abbas | G. N. Nogueras Gonzalez | S. Pierce | K. Sasaki | A. Maiti | G. Montalban-Bravo | M. Yilmaz | J. Alvarez | Michelle Golez